Stay updated on Dolatav Clinical Trial: Nucleoside Sparing in HIV-1

Sign up to get notified when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.
Latest website image capture
Clouds background image

Latest updates to the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page

  1. Check
    5 days ago
    Change Detected
    Summary
    The new screenshot shows only layout and styling adjustments with no changes to the study's title, objectives, eligibility criteria, endpoints, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-03T20:56:27.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    34 days ago
    Change Detected
    Summary
    Added a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.
    Difference
    3%
    Check dated 2025-10-06T05:20:03.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Version update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.
    Difference
    0.1%
    Check dated 2025-09-29T03:00:38.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Revision upgraded from v3.0.1 to v3.0.2; the Back to Top element was removed as a minor UI change.
    Difference
    0.2%
    Check dated 2025-09-14T18:58:38.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.2%
    Check dated 2025-09-07T14:17:56.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, as well as various organic chemical compounds. Notably, several key terms related to HIV and its treatments have been removed.
    Difference
    4%
    Check dated 2025-08-31T11:44:15.000Z thumbnail image

Stay in the know with updates to Dolatav Clinical Trial: Nucleoside Sparing in HIV-1

Enter your email address, and we'll notify you when there's something new on the Dolatav Clinical Trial: Nucleoside Sparing in HIV-1 page.